Overview of current treatment of juvenile-onset recurrent respiratory papillomatosis
Authors:
M. Formánek 1,2; H. Kučová 1; Karol Zeleník 1,2; Pavel Komínek 1,2
Authors‘ workplace:
Otorinolaryngologická klinika FN Ostrava
přednosta prof. MUDr. P. Komínek, Ph. D., MBA
1; Katedra kraniofaciálních oborů, Lékařská fakulta, Ostravská univerzita, Ostrava
vedoucí prof. MUDr. P. Komínek, Ph. D., MBA
2
Published in:
Čes-slov Pediat 2015; 70 (3): 174-178.
Category:
Reviews
Overview
Juvenile-onset recurrent respiratory papillomatosis (JRRP) is the most common benign neoplasm of the larynx in children. JRRP is caused by the human papillomavirus. It most commonly presents with hoarseness, stridor or respiratory distress.
The disease is potentially very aggressive and tends to recur and spread into the respiratory tract. The treatment of JRRP consists of surgical interventions, in severe cases often supplement by the use of adjuvant therapy such as cidofovir, interferon, anti-refux therapy and bevacizumab. It is possible to use human papillomavirus vaccines in some patients as a prophylaxis as well.
Key words:
juvenile-onset recurrent respiratory papillomatosis, therapy, human papilloma virus, cidofovir, HPV vaccination, bevacizumab
Sources
1. Gissmann L, Diehl V, Schultz-Coulon HJ, et al. Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol 1982; 44: 393–400.
2. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6 (4): 204.
3. Holland BW, Koufman JA, Postma GN, et al. Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas. Laryngoscope 2002; 112: 1926–1929.
4. McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol 2005; 69: 597–605.
5. Buchinsky FJ, Derkay CS, Leal SM, et al. Multicenter initiative seeking critical genes in respiratory papillomatosis. Laryngoscope 2004; 114: 349–357.
6. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995; 121: 1386–1391.
7. Morgan AH, Zitch RP. Recurrent respiratory papillomatosis in children: a retrospective study of management and complications. Ear Nose Throat J 1986; 65: 19–28.
8. Kashima HK, Shah F, Lyles A, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 1992; 102: 9–13.
9. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 (3): 35–41.
10. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125: 743–748.
11. Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001; 111: 57–69.
12. Rabah R, Lancaster WD, Thomas R, et al. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001; 4: 68–72.
13. Go C, Schwartz MR, Donovan DT. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann Otol Rhinol Laryngol 2003; 112: 298–302.
14. Derkay CS, Malis DJ, Zalzal G, et al. A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope 1998; 108 (6): 935–937.
15. Kopřivová H, Zeleník K, Komínek P. Současné možnosti léčby recidivující papilomatózy hrtanu. Otorinolaryng a Foniat (Prague) 2010; 59 (4): 235–240.
16. Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg 2008; 16: 536–542.
17. Holler T, Allegro J, Chadha NK, et al. Voice outcomes following repeated surgical resection of laryngeal papillomata in children. Otolaryngol Head Neck Surg 2009; 141: 522–526.
18. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125 (7):743–748.
19. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008, 118: 1236–1247.
20. Naiman AN, Ceruse P, Coulombeau B, et al. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope 2003; 113 (12): 2174–2181.
21. Goon P, Sonnex C, Jani P, et al. Recurrent respiratory papillomatosis: an overview of current thinking and treatment. Eur Arch Otorhinolaryngol 2008; 265 (2): 147–151.
22. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues – a survey. Antiviral Res 2001; 49 (2): 55–74.
23. Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol Head Neck Surg 2007; 136 (6): 863–869.
24. McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 2008; 117: 477–483.
25. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649–2651.
26. Buckmiller L, Dyanmenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope 2009; 119: 2051–2054.
27. Rahbar R, Vargas SO, Folkman J, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005; 114: 289–295.
28. López-Ocejo O, Viloria-Petit A, Bequet-Romero M, et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53-independent manner. Oncogene 2000; 19: 4611–4620.
29. Maturo S, Tse SM, Kinane TB, et al. Initial experience using propranolol as an adjunctive treatment in children with aggressive recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2011; 120 (1): 17–20.
30. Zeitels SM, Lopez-Guerra G, Burns JA, et al. Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol 2009; 201 (Suppl): 1–13.
31. Maturo S, Hartnick CJ. Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional Bevacizumab for aggressive respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 2010; 136 (6): 561–565.
32. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113 (10): 1695.e1–e15.
33. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114 (5): 855–859.
34. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 1991; 16: 59–66.
35. Bradlow HL, Michnovicz JJ, Telang NT, et al. Effect of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991; 12: 1571–1574.
36. Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004; 18 (2): 248–253.
37. Shikowitz MJ, Abramson AL, Freeman K, et al. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998; 108: 962–967.
38. Pashley NR. Can mumps vaccine induce remission in recurrent respiratory papilloma? Arch Otolaryngol Head Neck Surg 2002; 128 (7): 783–786.
39. Villa LL, Ault KA, Giuliano AR, et al. Imunologic response following administration of vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006; 24: 5571–5583.
40. Goldemund K, Máchalová M, Šlapák I, et al. Recidivující papilomatóza laryngu a změna průběhu onemocnění při vakcinaci proti humánnímu papillomaviru. Pediatr pro Praxi 2010; 11 (2): 115–117.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2015 Issue 3
Most read in this issue
- Cervical lymphadenopathy from the perspective of an otolaryngologist
- Mild mental retardation in ambulance of general practitioner for child and adolescent – can you recognize it?
- Segmental dilatation of the intestine – case series of newborns with segmental dilatation of the small intestine and a literature review
- Preparticipation examination in young athletes with focus on resting electrocardiogram